stoxline Quote Chart Rank Option Currency Glossary
Pacira BioSciences, Inc. (PCRX)
28.49  0.68 (2.45%)    12-04 16:00
Open: 27.89
High: 29.115
Volume: 376,011
Pre. Close: 27.81
Low: 27.77
Market Cap: 1,323(M)
Technical analysis
2023-12-04 4:24:27 PM
Short term     
Mid term     
Targets 6-month :  34.14 1-year :  36.52
Resists First :  29.23 Second :  31.27
Pivot price 27.53
Supports First :  25.93 Second :  21.57
MAs MA(5) :  27.62 MA(20) :  28.04
MA(100) :  32.54 MA(250) :  37.34
MACD MACD :  -0.5 Signal :  -0.7
%K %D K(14,3) :  52.1 D(3) :  37.9
RSI RSI(14): 52.3
52-week High :  48.59 Low :  25.93
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PCRX ] has closed below upper band by 14.2%. Bollinger Bands are 35.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 29.15 - 29.26 29.26 - 29.37
Low: 27.48 - 27.61 27.61 - 27.75
Close: 28.28 - 28.48 28.48 - 28.68
Company Description

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Headline News

Fri, 24 Nov 2023
Declining Stock and Decent Financials: Is The Market Wrong About Pacira BioSciences, Inc. (NASDAQ:PCRX)? - Simply Wall St

Mon, 13 Nov 2023
Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion - Nasdaq

Tue, 07 Nov 2023
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare ... - Yahoo Finance

Thu, 02 Nov 2023
Pacira BioSciences, Inc. 2023 Q3 - Results - Earnings Call ... - Seeking Alpha

Thu, 26 Oct 2023
Pacira to Report Third Quarter 2023 Financial Results on Thursday ... - Yahoo Finance

Wed, 11 Oct 2023
Amidst increasing losses, Investors bid up Pacira BioSciences (NASDAQ:PCRX) 7.7% this past week - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers—Specialty & Generic
Shares Out 46 (M)
Shares Float 46 (M)
Held by Insiders 1.2 (%)
Held by Institutions 105.8 (%)
Shares Short 3,190 (K)
Shares Short P.Month 3,930 (K)
Stock Financials
EPS 0.15
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 17.9
Profit Margin 1 %
Operating Margin 12.8 %
Return on Assets (ttm) 2.9 %
Return on Equity (ttm) 0.8 %
Qtrly Rev. Growth -2.1 %
Gross Profit (p.s.) 8.46
Sales Per Share 14.33
EBITDA (p.s.) 3.33
Qtrly Earnings Growth 0 %
Operating Cash Flow 149 (M)
Levered Free Cash Flow 123 (M)
Stock Valuations
PE Ratio 189.93
PEG Ratio 0.7
Price to Book value 1.59
Price to Sales 1.98
Price to Cash Flow 8.87
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android